*

Penny Stock DD

**Orexigen Therapeutics Inc. (OREX)**Premium Pick from Pennystockdd.com

September 3, 2010
[del.icio.us] [Digg] [Faves] [LinkedIn] [Reddit] [StumbleUpon] [Technorati] More »

5.43    +0.84 (+18.30%)View Help Stock Price Quote as of Thursday, Sep 2nd, 2010 (NASDAQ)
High 5.95 Low 5.42
52Wk High 10.83 52Wk Low 3.81
Open 5.78 Prev Close 4.59
Volume 9,260,407 Avg Volume 1,657,102

Orexigen Therapeutics Inc (NASDAQ: OREX) climbed 22.66% to $5.63. OREX has signed a $1 billion licensing deal with the Japan’s Takeda Pharmaceutical Co Ltd for the obesity drug, Contrave

OREXIGEN THERAPEUTICS, INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company’s lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates are designed to take advantage of the Company’s understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss.

Orexigen Therapeutics Inc (NASDAQ: OREX) climbed 22.66% to $5.63. OREX has signed a $1 billion licensing deal with the Japan’s Takeda Pharmaceutical Co Ltd for the obesity drug, Contrave.

Regards,

Don

: Stock Picks
:

Leave a Reply

Previous Post
«
Next Post
»
Bombax Theme designed by itx
Performance Optimization WordPress Plugins by W3 EDGE